20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Shares of Curis (NASDAQ:CRIS) decreased after the company reported Q4 results.
Quarterly Results
Earnings per share increased 57.69% year over year to ($0.11), which missed the estimate of ($0.09).
Revenue of $3,024,000 declined by 8.00% year over year, which beat the estimate of $2,840,000.
Guidance
Curis hasn't issued any earnings guidance for the time being.
Curis hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Mar 16, 2021
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1827/40133
Technicals
52-week high: $13.44
Company's 52-week low was at $0.62
Price action over last quarter: Up 778.51%
Company Description
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!